MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Recruiting
Phase 2
Interventional Study
Hematologic Malignancy
Acute Leukemia
Remission
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
AML
TP53
Intrachromosomal Amplification of Chromosome 21
Cytogenetic Abnormality
CNS Leukemia
Minimal Residual Disease
Myelodysplasia
Juvenile Myelomonocytic Leukemia
Somatic Mutation
PTPN11 Gene Mutation
N-RAS Gene Amplification
Neurofibromatosis 1
NF1 Mutation
CBL Gene Mutation
Monosomy 7
Chromosome Abnormality
Fetal Hemoglobin
Lymphoblastic Lymphoma
High Grade Non-Hodgkin's Lymphoma, Adult
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- Up to 60
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 70 (estimated)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety/feasibility study of the investigational procedure/product.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histological confirmation of hematological malignancies
* Acute leukemias
* Acute Myeloid Leukemia (AML) and related precursor neoplasms
* Favorable risk AML is defined as having one of the following:
* Acute lymphoblastic leukemia (ALL)/lymphoma
* Myelodysplasia (MDS) IPSS IN…
Contacts